Decision: Favourable

Decisions Table

Study Title:

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) c

  • NREC Code:

    22-NREC-CT-169

  • Decision:

    Favourable

  • Meeting Date:

    09/11/2022

  • Study Type:

    CT Application

  • Principal Investigator:

    Dr Maeve Crowley

  • PI Institution:

    Cork University Hospital

  • Sponsor:

    Anthos Therapeutics Inc.

Scroll to Top